SOUTH SAN FRANCISCO, Calif.–Fluxion Biosciences, Inc. announced today that it has launched an Early Access Program for its IsoFlux Rare Cell Access System. The program will enable scientists to incorporate circulating tumor cells (CTC) and other rare cell assays into their research prior to the IsoFlux commercial product release.

Circulating tumor cells disseminate from primary tumors and enter the peripheral bloodstream. These cells have been shown to contribute to the metastatic process in carcinomas such as breast, prostate, colorectal, and pancreatic cancer. A new generation of personalized cancer therapies is emerging built on the unique molecular signatures of each cancer patient’s disease status. The isolation and analysis of circulating tumor cells will play a pivotal role in identifying these molecular profiles and how they change over time.

“We are very excited to launch the IsoFlux Early Access Program,” commented Jeff Jensen, CEO. “The IsoFlux System enables access to rare but potentially very useful cells that will help deliver the next generation of cancer diagnostics and personalized medicine. We have been very encouraged by the data coming from our initial partnerships and are excited to offer this technology to the clinical and life science research community.”

The IsoFlux System utilizes a proprietary microfluidic technology to isolate rare cells with high efficiency. The sample gets processed under more controlled and uniform conditions than bulk separations. This contributes to increased efficiency, purity, and viability. The system incorporates CellSpot™ Technology which produces a highly concentrated sample that is optimized for downstream molecular analyses. A variety of downstream analytical techniques are available for the isolated cell samples such as polymerase chain reactions (PCR), microscopy, and immunoassays.

Typical applications for the IsoFlux System include isolation of circulating tumor cells, cancer stem cells, rare blood cells, endothelial cells, and stem cells. The product was initially developed through a grant from the National Cancer Institute and Fluxion has established partnerships with clinical research organizations, universities, biotechnology and pharmaceutical companies to further validate the technology. For more information about the IsoFlux System, or to participate in the Early Access Program, please visit http://www.fluxionbio.com/isoflux.

About Fluxion Biosciences

Fluxion Biosciences provides cellular analysis tools for use in critical life science, drug discovery, and diagnostic applications. Fluxion’s proprietary microfluidic platform enables precise functional analysis of individual cells in a multiplexed format. Products include the BioFlux™ System for studying cellular interactions, the IonFlux™ System for high throughput patch clamp measurements, and the IsoFlux™ System for rare cell access. Fluxion’s systems are designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. For more information about Fluxion Biosciences, visit www.fluxionbio.com.